Portfolio Alerts Watch List Cart

Healthcare

Refine Search


Product Compare (0)
A
Amrutanjan Health Care Ltd
Score 68/100• Decent
Amrutanjan Health Care Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
Company’s Health86/100
Valuation 20/100 · PB 6.0829
Technical Avoid
1M -10.556% 6M -1.87% 1Y -8.34%
Confidence100%
Low leverage (D/E)No promoter pledge
#106
View details ➜
A
Alembic Pharmaceuticals Ltd
Score 68/100• Decent
Alembic Pharmaceuticals shows potential for growth but faces challenges in profitability and market competition.
Company’s Health81/100
Valuation 40/100 · PB 3.3214
Technical Avoid
1M -3.204% 6M -11.656% 1Y -16.166%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#107
View details ➜
A
Akums Drugs and Pharmaceuticals Ltd
Score 68/100• Decent
Akums Drugs and Pharmaceuticals Ltd shows potential for growth, but faces challenges in profitability and market competition.
Company’s Health79/100
Valuation 60/100 · PB 2.1142
Technical Avoid
1M -2.17% 6M -25.696% 1Y -27.936%
Confidence100%
Low leverage (D/E)No promoter pledge
#108
View details ➜
G
GlaxoSmithKline Pharmaceuticals Ltd
Score 68/100• Decent
GlaxoSmithKline Pharmaceuticals Ltd shows decent fundamentals but faces challenges in profitability and market sentiment. It is a stable player in a growing sector, but caution is advised due to valuation concerns and execution risks.
Company’s Health84/100
Valuation 20/100 · PB 22.5793
Technical Avoid
1M 5.487% 6M -21.663% 1Y 12.877%
Confidence100%
Low leverage (D/E)No promoter pledge
#109
View details ➜
G
Gland Pharma Ltd
Score 68/100• Decent
Gland Pharma shows potential for growth but faces challenges in profitability and market competition.
Company’s Health86/100
Valuation 40/100 · PB 3.0223
Technical Avoid
1M -9.14% 6M 0.551% 1Y -5.832%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#110
View details ➜
F
Fischer Medical Ventures Ltd
Score 68/100• Decent
Fischer Medical Ventures Ltd shows potential but faces several challenges that may hinder growth and profitability.
Company’s Health73/100
Valuation 20/100 · PB 8.7356
Technical Avoid
1M -42.68% 6M -41.101% 1Y -41.101%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#111
View details ➜
F
F D C Ltd
Score 68/100• Decent
F D C Ltd shows potential for growth in a stable sector, but faces challenges in profitability and valuation metrics.
Company’s Health86/100
Valuation 60/100 · PB 2.9899
Technical Avoid
1M 4.162% 6M -9.083% 1Y -17.887%
Confidence100%
Low leverage (D/E)No promoter pledge
#112
View details ➜
D
Dr. Agarwal's Health Care Ltd
Score 68/100• Decent
Dr. Agarwal's Health Care Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should proceed with caution.
Company’s Health65/100
Valuation 20/100 · PB 8.2988
Technical Avoid
1M 0.696% 6M 35.845% 1Y 25.918%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#113
View details ➜
C
Concord Drugs Ltd
Score 68/100• Decent
Concord Drugs Ltd shows potential but faces significant challenges in growth and profitability metrics.
Company’s Health71/100
Valuation 60/100 · PB 2.4931
Technical Avoid
1M -6.841% 6M 179.776% 1Y 132.269%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#114
View details ➜
C
Caplin Point Laboratories Ltd
Score 68/100• Decent
Caplin Point Laboratories Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health100/100
Valuation 20/100 · PB 5.1718
Technical Avoid
1M 0.355% 6M -7.074% 1Y -19.461%
Confidence100%
Low leverage (D/E)No promoter pledge
#115
View details ➜
B
Brooks Laboratories Ltd
Score 68/100• Decent
Brooks Laboratories Ltd shows potential in a growing sector, but faces challenges in growth consistency and profitability metrics.
Company’s Health55/100
Valuation 60/100 · PB 2.9436
Technical Avoid
1M -6.098% 6M -22.19% 1Y -33.712%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#116
View details ➜
B
Blue Jet Healthcare Ltd
Score 68/100• Decent
Blue Jet Healthcare Ltd shows potential for growth but faces significant challenges in profitability and execution risks.
Company’s Health100/100
Valuation 20/100 · PB 8.5507
Technical Avoid
1M -5.291% 6M -42.071% 1Y 11.643%
Confidence100%
Low leverage (D/E)No promoter pledge
#117
View details ➜
A
Anlon Healthcare Ltd
Score 68/100• Decent
Anlon Healthcare Ltd shows potential for growth, but faces challenges in valuation and execution risks.
Company’s Health70/100
Valuation 20/100 · PB 9.3494
Technical Avoid
1M -4.5% 6M 54.213% 1Y 54.213%
Confidence100%
No promoter pledgeHealthy profit margins
#118
View details ➜
A
Aditya BSL Nifty Healthcare ETF
Score 68/100• Decent
The Aditya BSL Nifty Healthcare ETF shows potential for growth in a vital sector, but faces challenges in valuation and governance that investors should consider.
Company’s Health0/100
Valuation 0/100 · PB —
Technical Avoid
1M -1.655% 6M 3.336% 1Y -2.998%
Confidence80%
#119
View details ➜
A
Accretion Pharmaceuticals Ltd
Score 68/100• Decent
Accretion Pharmaceuticals Ltd shows potential but faces challenges in growth consistency and valuation metrics.
Company’s Health91/100
Valuation 20/100 · PB 6.943
Technical Momentum
1M 56.393% 6M 22.514% 1Y 15.13%
Confidence100%
No promoter pledgeDecent revenue growth
#120
View details ➜
Showing 106 to 120 of 301 (21 Pages)